WHO SAGE Recasts Vaccine Policy Across HPV, Outbreak Response and Polio
WHO’s Strategic Advisory Group of Experts on Immunization used its October meeting to redraw several lines in global vaccine policy, with decisions spanning HPV, diphtheria, yellow fever, mpox, polio and the ongoing Bundibugyo virus disease outbreak. The common thread was not simply where vaccines work, but how public health systems can use them under pressure, with finite supply, uneven coverage and recurring outbreaks.
A single dose can now carry more policy weight in HPV prevention.
Single-Dose HPV Strategy Meets a Coverage Gap That Remains Too Wide
For HPV vaccine, the latest review landed on a clear operational conclusion: a single-dose schedule for girls aged 9 to 14 years is the most efficient way to move coverage toward the 90% target. WHO’s message is grounded in a blunt epidemiologic reality. By the end of 2025, more than 95 million girls had received HPV vaccine, and 165 countries, or 85%, had introduced the vaccine. Even so, global coverage stood at 33% in 2025, far below the level needed to make cervical cancer elimination a realistic goal at population scale.
The logic here is straightforward. HPV vaccination works best when health systems can reach large cohorts quickly and repeatedly, but many countries are struggling to maintain routine delivery while also catching up children who missed immunizations during the pandemic. A one-dose strategy reduces programmatic friction, lowers the number of missed opportunities, and makes vaccine supply go further. WHO also extended the practical range by allowing a single dose for people up to 30 years old, a move that broadens the window for protection in settings where delivery constraints would otherwise slow progress.
Diphtheria Outbreaks Expose the Cost of Weak Primary Immunization
Diphtheria was treated as a warning signal rather than a narrow outbreak-management problem. Rising outbreaks usually mean the same thing: primary series coverage is too low, booster doses are being missed, or both. In that setting, the response cannot lean on mass vaccination alone. Case detection, diphtheria antitoxin therapy, and antibiotics for cases and close contacts sit at the center of outbreak control, while vaccination has a narrower role in the early phase of spread.
The emphasis on early response reflects the biology of the disease. Once transmission is established in a susceptible population, vaccination campaigns cannot instantly close immunity gaps; they work best when deployed before the outbreak expands, and their effect is strongest when routine services are already able to maintain protection over time. WHO’s guidance pushed hard toward a durable fix: strengthen routine immunization and booster delivery so that emergency campaigns are no longer carrying the burden of basic prevention.
Yellow Fever Doses Stretch Further When Supply Is Tight
Yellow fever policy moved in a different direction, but for the same reason: scarcity. WHO concluded that fractional doses, defined as one fifth of a standard dose, may continue to be used in outbreaks when supply constraints threaten timely vaccination. The guidance also supports fractional dosing in certain preventive campaigns when financial or programmatic limits would otherwise delay protection.
Standard dosing remains the recommendation for routine and catch-up vaccination in young children. The distinction is pragmatic and clinically important. In outbreaks, the best dose is often the one that can be delivered quickly enough to interrupt risk at scale. In routine childhood immunization, where timing and long-term protection matter more than immediate dose stretching, the standard dose remains the safer policy anchor. This is vaccine stewardship in the most literal sense: preserving protection while rationing limited supply to where it can prevent the most illness.
Mpox Policy Still Hobbled by Evidence Gaps in High-Risk Groups
Mpox remains on WHO’s agenda even after major outbreaks have subsided. The meeting reviewed vaccination for people at risk during outbreaks and the possible role of preventive vaccination before exposure in people at high risk of infection or severe disease. Yet the evidence base remains thin in several groups where decisions would matter most.
WHO identified critical gaps in epidemiology and vaccination evidence, and those gaps are large enough to block a policy recommendation for preventive use in children. More data are also needed in pregnant women and in people with severe immunocompromise. In practical terms, the policy message is restrained for a reason: when the downstream risk profile is uncertain, especially in vulnerable populations, recommendations must wait for better evidence rather than borrow confidence from adult outbreak data that may not generalize.
Polio Routine Immunization Cannot Sit at Two Doses
For polio, WHO’s position was direct. Countries that currently provide fewer than three doses of inactivated poliovirus vaccine through routine immunization should move without delay to a three-dose infant schedule. With wild poliovirus transmission still continuing in Afghanistan and Pakistan, the margin for error is too small to leave infant protection incomplete.
Here, the clinical and public health argument is closely aligned. Poliovirus transmission survives where immunity gaps persist, and routine immunization is the mechanism that closes those gaps before outbreaks flare. A two-dose schedule leaves too much room for vulnerability in communities where access is uneven, surveillance is imperfect, or booster catch-up is inconsistent. WHO’s guidance puts routine protection ahead of convenience.
Bundibugyo Virus Disease Demands Research, Not Assumptions
The Bundibugyo virus disease outbreak brought the sharpest edge of the meeting into view. WHO expressed deep concern about how difficult the outbreak has been to control and about the number of young children who have died. It reaffirmed that Ervebo, a vaccine licensed for Ebola virus disease, should be used only within research protocols in this setting.
That caution is tied to one fact: efficacy against Bundibugyo virus disease has not yet been established. The TUMAINI randomized controlled trial, which began on 23 October 2026, is expected to generate urgently needed evidence on whether any vaccine candidates, including Ervebo, are effective. The trial’s value goes beyond this outbreak. If it answers the question decisively, future outbreak policy could move from improvised response to evidence-based deployment. If it does not, communities will still need protection, but policy will have to remain honest about the limits of current data.
Evidence, Equity and National Delivery Will Decide What Happens Next
Across all of these decisions, WHO returned to the same operating principle: recommendations must evolve with the evidence and with the public health need. SAGE can define what should be done, but national immunization technical advisory groups and country programmes determine whether those recommendations become real-world protection. Budgets are tightening, birth cohorts are growing in many African countries, and routine immunization systems are still recovering from pandemic-era disruption. Those pressures make vaccine policy harder, not less urgent.
The meeting closed on a simple but demanding point. Recommendations alone do not protect communities. They only matter when countries can translate them into routine coverage, outbreak response, and sustained delivery for the people most at risk. In the absence of that translation, the same immunity gaps that fuel diphtheria, polio and other vaccine-preventable diseases will keep reopening, one missed dose at a time.